人 B 細(xì)胞前體白血病細(xì)胞系 YCUB-5 / Human B Cell Precursor Leukemia Cell Line YCUB-5

數(shù)據(jù)表 / Datasheet

細(xì)胞系信息

• 名稱：BioVector? YCUB-5 細(xì)胞系

• 詳細(xì)名稱：人 B 細(xì)胞前體白血病細(xì)胞系 YCUB-5（攜帶 ETV6::RUNX1 融合基因）

• 來源：來源于一名 9 歲男孩 B 細(xì)胞前體急性淋巴細(xì)胞白血病（BCP-ALL）患者的外周血

• 細(xì)胞類型：B 細(xì)胞前體白血?。˙CP-ALL）

• 形態(tài)：小而圓的細(xì)胞，懸浮生長，呈單細(xì)胞狀態(tài)

• 免疫表型：CD10+、CD19+、CD20+、CD34+、CD38+、HLA-DR+、TdT+；CD3-、CD13-、CD33-、CD45RA+、CD58+

• 主要遺傳特征：攜帶 ETV6::RUNX1（TEL::AML1）融合基因，為 t(12;21)(p13;q22) 易位的產(chǎn)物

• 其他特征：CD34 陽性提示該細(xì)胞系代表較早期的 B 細(xì)胞前體階段；對化療藥物具有特定的敏感性譜

• 病毒檢測：EBV-、HBV-、HCV-、HIV-1-、HIV-2-、HTLV-1/2-、MLV-

• 支原體檢測：PCR 檢測陰性

• STR 鑒定：通過 STR 分析驗證，與參考數(shù)據(jù)庫匹配

培養(yǎng)條件

• 培養(yǎng)基：BioVector? RPMI 1640 培養(yǎng)基，添加 10% BioVector? 胎牛血清

• 添加劑：建議添加 2 mM BioVector? L-谷氨酰胺

• 培養(yǎng)環(huán)境：37°C，5% CO?，飽和濕度

• 傳代方法：初始接種密度為 2–3 × 10? 個細(xì)胞/mL；每 2–3 天按 1:2 至 1:4 比例傳代；維持細(xì)胞密度在 3–8 × 10? 個細(xì)胞/mL

• 凍存液：BioVector? 胎牛血清含 5–10% BioVector? DMSO

• 生物安全等級：BSL-1（建議按 BSL-2 操作）

特征與用途

• 攜帶 ETV6::RUNX1 融合基因，是兒童急性淋巴細(xì)胞白血病中最常見的染色體易位類型，廣泛用于研究該融合基因在白血病發(fā)生、維持及預(yù)后中的作用機制

• 作為 ETV6::RUNX1 陽性細(xì)胞系模型，可用于研究該融合基因?qū)?xì)胞增殖、分化、凋亡及化療敏感性的調(diào)控

• 在藥物篩選研究中，用于評估新型靶向藥物對該亞型白血病的療效

• CD34 陽性、CD20 陽性表型使其適用于研究 B 細(xì)胞分化發(fā)育過程中 CD20 的表達(dá)調(diào)控及抗 CD20 靶向治療的敏感性

Cell Line Information

• Name: BioVector? YCUB-5 Cell Line

• Detailed Name: Human B Cell Precursor Leukemia Cell Line YCUB-5 (carrying ETV6::RUNX1 fusion)

• Source: Derived from the peripheral blood of a 9-year-old boy with B-cell precursor acute lymphoblastic leukemia (BCP-ALL)

• Cell Type: B cell precursor leukemia (BCP-ALL)

• Morphology: Small, round cells growing singly in suspension

• Immunophenotype: CD10+, CD19+, CD20+, CD34+, CD38+, HLA-DR+, TdT+; CD3-, CD13-, CD33-, CD45RA+, CD58+

• Key Genetic Features: Carries the ETV6::RUNX1 (TEL::AML1) fusion gene resulting from t(12;21)(p13;q22) translocation

• Other Features: CD34 positivity indicates an earlier B-cell precursor stage; exhibits a specific sensitivity profile to chemotherapeutic agents

• Virus Testing: Negative for EBV, HBV, HCV, HIV-1, HIV-2, HTLV-1/2, MLV

• Mycoplasma: Negative by PCR assay

• Authentication: Verified by STR analysis matching the reference database

Culture Conditions

• Medium: BioVector? RPMI 1640 supplemented with 10% BioVector? fetal bovine serum

• Additives: 2 mM BioVector? L-glutamine recommended

• Culture Environment: 37°C, 5% CO?, humidified atmosphere

• Subculturing: Seed at 2–3 × 10? cells/mL initially; split at 1:2 to 1:4 ratio every 2–3 days; maintain cell density between 3–8 × 10? cells/mL

• Cryopreservation: BioVector? fetal bovine serum with 5–10% BioVector? DMSO

• Biosafety Level: BSL-1 (standard BSL-2 practices recommended)

Characteristics & Applications

• Carries the ETV6::RUNX1 fusion gene, the most common chromosomal translocation in pediatric acute lymphoblastic leukemia; widely used to study the pathogenic mechanisms of this fusion in leukemogenesis, maintenance, and prognosis

• Serves as an ETV6::RUNX1-positive cell line model for investigating the regulatory roles of this fusion gene in cell proliferation, differentiation, apoptosis, and chemotherapy sensitivity

• Used in drug screening studies to evaluate the efficacy of novel targeted therapies against this leukemia subtype

• CD34-positive and CD20-positive immunophenotype makes it suitable for studying CD20 expression regulation during B-cell differentiation and sensitivity to CD20-targeted therapy

BioVector NTCC質(zhì)粒載體菌株細(xì)胞蛋白抗體基因保藏中心

電話:400-800-2947

工作QQ/微信同號:1843439339

網(wǎng)址http://www.nedfriskphoto.com